Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 1 / Phase 2	2026-04-13		NCT07164976

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nagoya City University	5
Novartis	114

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Nagoya City University	Nagoya	Japan	4

Clinical trials